Macrophages are critical for the initiation and resolution of the inflammatory phase of wound repair. In diabetes, macrophages display a prolonged inflammatory phenotype in late wound healing. Recently, Mixed-Lineage Leukemia-1 (MLL1) has been shown to direct gene expression by regulating NFκB-mediated inflammatory gene transcription. Thus, we hypothesized that MLL1 influences macrophage-mediated inflammation in wound repair. We utilized a myeloid-specific Mll1 knockout(Mll1(f/f)Lyz2(Cre+) ) to determine the function of MLL1 in wound healing. Mll1(f/f)Lyz2(Cre+) mice display delayed wound healing and decreased wound macrophage inflammatory cytokine production compared to controls. Further, wound macrophages from Mll1(f/f)Lyz2(Cre+) mice demonstrated decreased Histone-3 Lysine-4 trimethylation (H3K4me3; activation mark) at NFκB-binding sites on inflammatory gene promoters. Interestingly, early wound macrophages from 'pre-diabetic' mice displayed similarly decreased MLL1, H3K4me3 at inflammatory gene promoters, and inflammatory cytokines compared to controls. Importantly, late wound macrophages from 'pre-diabetic' mice demonstrated an increase in MLL1, H3K4me3 at inflammatory gene promoters, and inflammatory cytokines. 'Pre-diabetic' macrophages treated with an MLL1 inhibitor demonstrated reduced inflammation. Finally, monocytes from type-2 diabetic(T2D) patients had increased Mll1 compared to non-diabetic controls. These results define an important role for MLL1 in regulating macrophage-mediated inflammation in wound repair and identify a potential target for the treatment of chronic inflammation in diabetic wounds.